- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|Approved drug?||Yes (EMA & FDA (2018))|
|International Nonproprietary Names|
|burosumab-twza | Crysvita® | KRN-23 | KRN23 | N5KG1_C10_LH | UX-023 | UX023|
|Burosumab (KRN23) is a fully human anti-FGF-23 monoclonal antibody. Anti-FGF-23 mAbs are considered suitable for prevention or treatment of diseases which are caused by hyperactivity of FGF-23 or for diseases whose pathology might be improved by controlling FGF-23 activity.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent US7883705, with the claimed antibody being abbreviated to 'C10' in the document (full identifier N5KG1_C10_LH) .
|GtoPdb PubChem SID||318164811|
|Search PubMed clinical trials||burosumab|
|Search PubMed titles||burosumab|
|Search PubMed titles/abstracts||burosumab|